Last updated: 21 July 2022 at 5:22pm EST

Joshua Levine Net Worth




The estimated Net Worth of Joshua Levine is at least $7.97 Milione dollars as of 30 September 2021. Mr. Levine owns over 15,741 units of Accuray Inc stock worth over $2,144,306 and over the last 12 years he sold ARAY stock worth over $1,179,102. In addition, he makes $4,644,990 as President, Chief Executive Officer e Director at Accuray Inc.

Mr. Levine ARAY stock SEC Form 4 insiders trading

Joshua has made over 20 trades of the Accuray Inc stock since 2013, according to the Form 4 filled with the SEC. Most recently he sold 15,741 units of ARAY stock worth $62,334 on 30 September 2021.

The largest trade he's ever made was buying 100,000 units of Accuray Inc stock on 3 November 2014 worth over $634,000. On average, Joshua trades about 12,742 units every 62 days since 2012. As of 30 September 2021 he still owns at least 1,088,480 units of Accuray Inc stock.

You can see the complete history of Mr. Levine stock trades at the bottom of the page.





Joshua Levine biography

Joshua H. Levine is a President, Chief Executive Officer, Director of the Company. He has been the President, Chief Executive Officer, and a director of two other publicly traded global medical device firms, including Mentor Corporation, a surgical implant/medical device manufacturer in the aesthetics space from 2004 to 2009, and, prior to joining Accuray, with Immucor Corporation, a diagnostics manufacturer of automated instrumentation and reagents used in blood transfusion procedures. Mr. Levine currently serves on the Board of Directors of Natus Medical Incorporated, a provider of medical devices, software and services for the newborn care, neurology, sleep, hearing and balance markets. Mr. Levine holds a B.A. from the University of Arizona. Mr. Levine brings diverse, global healthcare industry experience and a strong track record of creating and unlocking strategic value for the companies he has led. Mr. Levine’s qualifications to serve on our Board include, among other skills and qualifications, his strategic business development skills, commercial leadership experience and executive vision. In addition, Mr. Levine brings expertise in the medical device and medical technology industries from years of experience as a chief executive officer with two other publicly traded, small cap medical device manufacturing companies.

What is the salary of Joshua Levine?

As the President, Chief Executive Officer e Director of Accuray Inc, the total compensation of Joshua Levine at Accuray Inc is $4,644,990. There are 1 executives at Accuray Inc getting paid more, with Ali Pervaiz having the highest compensation of $5,183,662.



How old is Joshua Levine?

Joshua Levine is 61, he's been the President, Chief Executive Officer e Director of Accuray Inc since 2012. There are 5 older and 10 younger executives at Accuray Inc. The oldest executive at Accuray Inc is Elizabeth Davila, 75, who is the Independent Director.

What's Joshua Levine's mailing address?

Joshua's mailing address filed with the SEC is Chesapeake Terrace, Sunnyvale, Santa Clara County, California, 94089, United States.

Insiders trading at Accuray Inc

Over the last 18 years, insiders at Accuray Inc have traded over $37,863,458 worth of Accuray Inc stock and bought 806,995 units worth $5,047,672 . The most active insiders traders include International Investment Ho..., Robert S Weiss e Euan Thomson. On average, Accuray Inc executives and independent directors trade stock every 24 days with the average trade being worth of $62,792. The most recent stock trade was executed by Ali Pervaiz on 4 September 2024, trading 8,404 units of ARAY stock currently worth $17,312.



What does Accuray Inc do?

accuray incorporated (nasdaq: aray) is a radiation oncology company that develops, manufactures and sells precise, innovative tumor treatment solutions that set the standard of care with the aim of helping patients live longer, better lives. the company's leading-edge technologies deliver the full range of radiation therapy and radiosurgery treatments. for more information, please visit www.accuray.com. for career opportunities, please visit http://www.accuray.com/careers.



What does Accuray Inc's logo look like?

Accuray Inc logo

Complete history of Mr. Levine stock trades at Accuray Inc e Natus Medical Inc

Data
#
Ditta
Persona
Trans.
Transazione
Azioni Prezzo per azione Prezzo totale Azioni dopo Fonte
30 Sep 2021 Joshua Levine
CEO
Vendita 15,741 $3.96 $62,334
30 Sep 2021
1,088,480
18 Aug 2021 Joshua Levine
CEO
Acquistare 15,000 $3.63 $54,450
18 Aug 2021
1,104,221
30 Nov 2020 Joshua Levine
CEO
Vendita 15,674 $4.07 $63,793
30 Nov 2020
1,029,538
2 Oct 2020 Joshua Levine
CEO
Vendita 15,370 $2.43 $37,349
2 Oct 2020
764,943
4 Dec 2019 Joshua Levine
CEO
Vendita 17,587 $2.74 $48,188
4 Dec 2019
1,331,966
31 Oct 2019 Joshua Levine
CEO
Vendita 28,081 $2.61 $73,291
31 Oct 2019
931,063
1 Oct 2019 Joshua Levine
CEO
Vendita 18,023 $2.72 $49,023
1 Oct 2019
959,144
2 Jul 2019 Joshua Levine
CEO
Vendita 56,426 $3.75 $211,598
2 Jul 2019
977,167
2 Apr 2019 Joshua Levine
CEO
Vendita 6,604 $4.54 $29,982
2 Apr 2019
1,033,593
30 Nov 2018 Joshua Levine
CEO
Vendita 15,839 $4.00 $63,356
30 Nov 2018
1,340,197
5 Nov 2018 Joshua Levine
CEO
Acquistare 25,000 $4.75 $118,750
5 Nov 2018
1,356,036
31 Oct 2018 Joshua Levine
CEO
Vendita 43,257 $4.66 $201,578
31 Oct 2018
1,331,036
2 Oct 2018 Joshua Levine
CEO
Vendita 17,242 $4.38 $75,520
2 Oct 2018
1,374,293
3 Jul 2018 Joshua Levine
CEO
Vendita 34,235 $4.08 $139,679
3 Jul 2018
1,392,518
3 Apr 2018 Joshua Levine
CEO
Vendita 8,675 $4.65 $40,339
3 Apr 2018
1,426,753
1 Dec 2017 Joshua Levine
CEO
Vendita 17,093 $4.86 $83,072
1 Dec 2017
1,435,428
9 Nov 2015 Joshua Levine
CEO
Acquistare 50,000 $7.12 $356,000
9 Nov 2015
1,115,830
3 Nov 2014 Joshua Levine
CEO
Acquistare 100,000 $6.34 $634,000
3 Nov 2014
811,643
6 May 2014 Joshua Levine
CEO
Acquistare 50,000 $8.15 $407,500
6 May 2014
531,210
13 Feb 2013 Joshua Levine
CEO
Acquistare 100,000 $4.38 $438,000
13 Feb 2013
300,000


Accuray Inc executives and stock owners

Accuray Inc executives and other stock owners filed with the SEC include: